IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

By Drug Class;

TNF Inhibitors, Amino salicylates, Integrin Antagonists, Corticosteroids, and Others

By Route of Administration;

Oral and Injectable

By Disease Indication;

Ulcerative Colitis and Crohn’s Disease

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn100960009 Published Date: August, 2025

IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Overview

IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market (USD Million)

IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market was valued at USD 22,190.80 million in the year 2024. The size of this market is expected to increase to USD 36,576.57 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.4%.


IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

*Market size in USD million

CAGR 7.4 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.4 %
Market Size (2024)USD 22,190.80 Million
Market Size (2031)USD 36,576.57 Million
Market ConcentrationMedium
Report Pages319
22,190.80
2024
36,576.57
2031

Major Players

  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Johnson & Johnson
  • Ferring Pharmaceuticals
  • Eli Lilly and Company
  • Bristol Myers Squibb
  • UCB S.A.
  • Celgene Corporation (a subsidiary of Bristol Myers Squibb)
  • GlaxoSmithKline plc

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

Fragmented - Highly competitive market without dominant players


The IBD Treatment Market, which includes therapies for ulcerative colitis and Crohn’s disease, is expanding steadily as more patients gain access to advanced medical options. Over 55% of patients now choose biologics and modern therapies over conventional drugs, reflecting a growing reliance on innovative treatments. Rising diagnosis rates and treatment accessibility are key factors supporting this momentum.

Key Drivers Accelerating Growth
The emphasis on biologics, biosimilars, and precision-based therapies significantly strengthens the market. Data shows that more than 48% of patients experience improved quality of life with biologic therapies. Increasing investments in immune-modulating solutions continue to boost treatment effectiveness, fueling broader adoption across healthcare providers.

Advancements Strengthening Market Adoption
Pharmaceutical companies and clinical institutions represent nearly 60% of treatment adoption, integrating evidence-based protocols into routine practice. Surveys reveal that almost 65% of specialists recommend biologics or biosimilars as first-line therapy for moderate-to-severe cases. This strong clinical backing reinforces confidence in advanced therapeutic options.

Growth Prospects and Industry Outlook
The IBD Treatment Market demonstrates promising potential, backed by continuous patient-focused innovations and research-driven advancements. Insights indicate that over 62% of industry stakeholders expect next-generation biologics and personalized medicine to dominate future therapies. With precision healthcare shaping treatment approaches, the market is positioned for long-term growth and improved patient outcomes.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Route of Administration
    3. Market Snapshot, By Disease Indication
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of IBD
        2. Advancements in Treatment Options
        3. Growing Awareness and Diagnosis Rates
      2. Restraints
        1. High Cost of Biologic Therapies
        2. Potential for Adverse Effects
        3. Limited Access to Affordable Treatment Options
      3. Opportunities
        1. Ongoing Research and Development Efforts
        2. Focus on Personalized Medicine
        3. Expansion of Healthcare Infrastructure
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market, By Drug Class, 2021 - 2031 (USD Million)
      1. TNF Inhibitors
      2. Aminosalicylates
      3. Integrin Antagonists
      4. Corticosteroids
      5. Others
    2. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market, By Route of Administration, 2021 - 2031 (USD Million)
      1. Oral

      2. Injectable

    3. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market, By Disease Indication, 2021 - 2031 (USD Million)
      1. Ulcerative Colitis
      2. Crohn’s Disease
    4. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market, By Distribution Channel, 2021 - 2031 (USD Million)

      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    5. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AbbVie Inc.
      2. Takeda Pharmaceutical Company Limited
      3. Pfizer Inc.
      4. Johnson & Johnson
      5. Ferring Pharmaceuticals
      6. Eli Lilly and Company
      7. Bristol Myers Squibb
      8. UCB S.A.
      9. Celgene Corporation (a subsidiary of Bristol Myers Squibb)
      10. GlaxoSmithKline plc
  7. Analyst Views
  8. Future Outlook of the Market